On Wednesday, October 5, the Kaiser Family Foundation hosted a live webinar to discuss proposals for controlling prescription drug costs. Panelists examined pros and cons of various proposed approaches and assessed the likelihood of their implimentation. Dana Goldman, an invited panelist and the Co-Chair of IVI's Panel of Health Advisors, focused on issues of access, pricing, value and innovation in his comments.
Read more here.
Viewpoint 6/30/16Goldman in Modern Healthcare: Take A Lesson From Vaccines
In a commentary for Modern HealthcareREAD MORE
Viewpoint 8/26/16Goldman tackles EpiPen pricing controversy in STAT News
Goldman addresses the firestorm created by Mylan's dramatic price hikes for their EpiPen in a new commentary published in STAT News: "To Prevent Another EpiPen Controversy, the Government Should Step In."READ MORE